Precision

Analogue Records Net Profit of HK$251.5 Million in FY2023

Retrieved on: 
Monday, March 25, 2024
ICBT, Biophysical environment, Transient-voltage-suppression diode, Building automation, Building, Information, BMS, Precision, Internet of things, Mechanical, ELV, MIC, JCW, TEI, Communication, Multi, Safety, Municipal solid waste, HK1, ESG, Acquisition, MEP, Electricity, Digital twin, Escalator, Engineering, E&M, Building information modeling, O&M, Information and communications technology, Growth, Lift, Water, Business model, Government

-- Profit attributable to owners of the Company increased to HK$251.5 million, a year-on-year growth of 119.5%

Key Points: 
  • -- Profit attributable to owners of the Company increased to HK$251.5 million, a year-on-year growth of 119.5%
    The Group's revenue for the Year was HK$6,132.9 million and gross profit was HK$833.3 million.
  • Profit attributable to owners of the Company was HK$251.5 million, representing a year-on-year increase of 119.5%.
  • The Group's contracts-in-hand remained at a high level of HK$11,459.6 million, providing a solid foundation for the business going forward.
  • Revenue of the Environmental Engineering segment grew by 9.9% to HK$1,356 million year-on-year, with contracts-in-hand amounting to HK$4,165 million as at 31 December 2023.

Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer

Retrieved on: 
Monday, April 8, 2024
Speech, GSK plc, Dexcom, ALS, Paralysis, Diabetes, Patient, Conditional sentence, Instrument, Heel, Electronics, Research, Otis, News, University, Computer engineering, Electricity, G7, Precision, FDA, Movement, Medical device

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.
  • He was one of the co-founders of Verily, Alphabet Inc.’s healthcare and life sciences company, where he served as Chief Technical Officer and Fellow from 2015 through 2022.
  • He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology, from discovery to manufacturing.
  • Under Otis’ technical leadership, Verily entered a number of significant collaborations with leading healthcare and pharmaceutical partners.

Precision Drilling Corporation Announces Filing of Management Information Circular, Virtual-Only Annual and Special Meeting of Shareholders, and 2023 ESG Performance Data

Retrieved on: 
Wednesday, April 3, 2024
Annual, Computershare, PD, Proxy, ESG, Internet, Precision Drilling, GRI, TSX, Sustainability accounting, TCFD, Special, Precision, Mountain, PDS, Annual general meeting

CALGARY, Alberta, April 03, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing of its Management Information Circular (the Circular) issued in connection with the 2024 Annual and Special Meeting of Shareholders (the Annual Meeting).

Key Points: 
  • CALGARY, Alberta, April 03, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing of its Management Information Circular (the Circular) issued in connection with the 2024 Annual and Special Meeting of Shareholders (the Annual Meeting).
  • Precision’s Annual Meeting will be held on Thursday, May 16, 2024 at 10:00 a.m. (Mountain Time) for holders of its common shares (Shareholders).
  • The virtual-only meeting format will provide all Shareholders an equal opportunity to participate in the Annual Meeting regardless of their geographic location.
  • Please see below and the Circular for details and instructions on participating and voting at the Annual Meeting.

Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Fulvestrant, NMPA, AstraZeneca, Disease, Progression-free survival, CDX, Boehringer Ingelheim, Patient, Webcast, NGS, Hospital, Breast, Breakthrough, Safety, HR, Depreciation, ID, Precision, Food, Marketing, FDA, Cryptocurrency

Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.

Key Points: 
  • Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.
  • Total value of new contracts entered into during 2023 amounted to RMB310 million, representing a 24% increase from 2022.
  • Revenues were RMB121.1 million (US$17.1 million) for the three months ended December 31, 2023, representing a 14.9% decrease from RMB142.2 million for the same period in 2022.
  • Burning Rock will host a conference call to discuss the fourth quarter and full year 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on March 29, 2024.

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Checkmate, Prevalence, Patient, World Games, SWOT, Biomarker, Research, NCCN, Cancer, EMA, Contract research organization, National Comprehensive Cancer Network, Protein, Medicine, Clinical trial, Drug development, Therapy, Precision, FDA, Pharmaceutical industry

Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.

Key Points: 
  • Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.
  • The Precision Oncology - Global Clinical Trial Landscape whitepaper is designed for researchers, clinicians, pharmaceutical, biopharma and biotech firms.
  • It presents a thorough analysis of healthcare, technology, macroeconomic, regulatory trends, SWOT analysis, funding, and innovative research developments in precision oncology.
  • The report provides a detailed review of the current precision oncology landscape including standout trials, important trends around FDA approvals, funding initiatives, and ongoing insights impacting research and development.

Ancora Issues Letter to Fellow Shareholders Regarding Norfolk Southern’s Failures of Diligence and Poor Judgment in Appointing John Orr as COO

Retrieved on: 
Friday, April 5, 2024
Professional Services, Insurance, Finance, Asset Management, Consulting, Banking, Letter, Exercise, Canadian Pacific Railway, Precision, History, Transport, Disclosure, Surface Transportation Board, KCS, Road, Workplace, Employment, CPKC, Risk, Woman, CSX, Illinois Central Railroad, Safety, CSX Corporation, Depression, Canadian National Railway, EVP, PSR, Meridian Speedway, NSC, Annual general meeting, Weakness, Female, Behavior, Verbal abuse, Security (finance)

Ohio-based Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”), which owns a large equity stake in Norfolk Southern Corporation (NYSE: NSC) (“Norfolk Southern” or the “Company”), today issued the below letter to fellow shareholders regarding the Board of Directors’ (the “Board”) apparent failures of diligence and poor judgment in appointing John Orr as COO.

Key Points: 
  • Ohio-based Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”), which owns a large equity stake in Norfolk Southern Corporation (NYSE: NSC) (“Norfolk Southern” or the “Company”), today issued the below letter to fellow shareholders regarding the Board of Directors’ (the “Board”) apparent failures of diligence and poor judgment in appointing John Orr as COO.
  • Ancora is a sizable shareholder of Norfolk Southern, meaning our interests and your interests are squarely aligned.
  • The Board and Mr. Shaw provided CPKC with excessive financial and strategic consideration that weakens Norfolk Southern’s long-term competitive positioning.
  • Norfolk Southern operated from a position of desperation, and shareholders and other stakeholders now stand to pay a steep price.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Stryker launches Gamma4 Hip Fracture Nailing System in Europe

Retrieved on: 
Tuesday, March 26, 2024
General Health, Surgery, Medical Devices, Health, Health Technology, Certification, Database, Gamma, CE, Hip, Fracture, Femur, Surgeon, Workflow, Trochanter, SYK, Precision, Multimedia, Nail, Feedback

Stryker (NYSE:SYK), a global leader in medical technologies, today announced the release of its Gamma4 Hip Fracture Nailing System in most of the European markets.

Key Points: 
  • Stryker (NYSE:SYK), a global leader in medical technologies, today announced the release of its Gamma4 Hip Fracture Nailing System in most of the European markets.
  • The newest Gamma system will provide surgeons with the next generation of Stryker’s intramedullary nailing system.
  • The Gamma4 system is designed to treat hip and femur fractures and streamline procedural workflows for surgeons.
  • The new Gamma4 system redefines hip fracture care with sleek instrumentation, advanced nail design and improved geometry collectively, ensuring a lasting impact on orthopaedic practices for years to come.”

Elevating Societal Impact: Matter’s Precision Group Expands Client Base in Sustainability and Nonprofit Categories

Retrieved on: 
Tuesday, March 26, 2024
Software, Media, Philanthropy, Sustainability, Technology, Environment, Public Relations, Investor Relations, Green Technology, Marketing, Advertising, Content Marketing, Communications, Other Philanthropy, PR, Organization, Growth, Communication, Matter, Precision, CMO, Multimedia

Matter Communications – a Brand Elevation Agency integrating PR, marketing and creative services – today announced the growth of its Precision group, a PR and content division of Matter that provides highly focused programs to support brands’ biggest business drivers, in sustainability/Greentech and nonprofit categories.

Key Points: 
  • Matter Communications – a Brand Elevation Agency integrating PR, marketing and creative services – today announced the growth of its Precision group, a PR and content division of Matter that provides highly focused programs to support brands’ biggest business drivers, in sustainability/Greentech and nonprofit categories.
  • The concerted efforts of the team represent the agency’s commitment to serving the missions of brands that actively seek to improve communities, causes and the environment of the world around us.
  • “We see the Precision team at Matter as an extension of our internal team, helping to elevate our company in key trade, business and regional media.
  • This is why Precision was built!”
    To learn more about Matter’s Precision group, please visit the Matter Precision Page .